PREDNISONE TABLETS
Prostate Small Cell Neuroendocrine Carcinoma
Fred Hutchinson Cancer CenterSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Prostate Small Cell Neuroendocrine Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin M.D. Anderson Cancer Center | Phase 2 | BB |
Pembrolizumab Rahul Aggarwal | Phase 2 | B |
CABAZITAXEL M.D. Anderson Cancer Center | Phase 2 | B |
Alisertib Weill Medical College of Cornell University | Phase 2 | B |
Abiraterone Acetate University of Washington | Phase 2 | CCC |
View all 22 →
Same molecule, other indications
PREDNISONE TABLETS is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →